



The advertisement features a photograph of a family—a man, a woman, and a young girl—walking on a beach at sunset. The girl is in the foreground, reaching out towards the camera. In the background, the ocean waves are visible. To the right of the photo is the LUMIGAN logo, which consists of a stylized sunburst icon above the word "LUMIGAN" in a large, blue, serif font. Below the name, in a smaller font, it says "(bimatoprost ophthalmic solution) 0.03%". Underneath that, there is a call to action: "Click here for more information about LUMIGAN®". At the bottom right of the advertisement, the Allergan logo and copyright information are visible: "ALLERGAN ©2005 Allergan, Inc., Irvine, CA 92612 ® Marks owned by Allergan, Inc."

[Glaucoma NEWS](#)

[Back to Home](#)

New System for Treating Glaucoma

In mid-February, Solx Inc., a Boston University Photonics Center Company (Boston, MA), began training ophthalmologists in Madrid, Spain, how to use the company's DeepLight Glaucoma Treatment System. Designed to lower IOP, the system differs from technologies for argon laser trabeculoplasty and selective laser trabeculoplasty in that it employs a titanium sapphire laser, which can be used with or without the company's gold shunt. According to the creator of the DeepLight Glaucoma Treatment System, Doug Adams, the titanium sapphire laser penetrates up to 95% of trabecular meshwork cells with little to no thermal damage. Adams, who is also the president and CEO of Solx, says such deep penetration significantly decreases IOP in as few as 24 hours.

The titanium sapphire laser has already received approval for use in Europe and Canada. The system will be sold in Europe starting in April, and Solx is currently conducting phase 3 clinical trials of the laser in the US.